Alteration in the gut microbiota and in the intestinal permeability has also been linked to NAFLD. Robust experimental data suggest endotoxemia is a trigger for hepatic inflammation leading to non-alcoholic steatohepatitis (NASH) and NAFLD progression. 2, 3 However, data from human studies remained controversial. 4, 5 Pang and coworkers examined the relationship between markers of endotoxemia and liver damage in patients with NAFLD. 6 They measured circulating levels of Lipopolysaccharide (LPS) and LPS binding protein (LBP), a stable biomarker reflecting hepatic LPS exposure in 237 Asian patients with histological NAFLD. First, authors tested whether endotexemia is associated with liver damage, and found that LBP was independently associated with hepatocellular damage and fibrosis, while LPS only with fibrosis. These data lend support to the hypothesis that endotoxemia is involved in the pathogenesis of NASH and promotion of fibrogenesis.
Next, they examined the determinants of endotoxemia. LBP levels were associated with male gender and metabolic risk factors.
Carriers of TM6SF2 rs58542926 C>T, encoding for the E167K lossof-function protein variant had also higher LBP levels. The E167K variant predisposes to NAFLD by impairing apoliprotein B (APOB) containing lipoprotein secretion by hepatocytes. Indeed, the mutation is associated with reduced fasting circulating lipoprotein concentration. 7, 8 TM6SF2 silencing in the liver results in steatosis due to decreased secretion of very low-density lipoproteins (VLDL)-associated lipids, 7 possibly by decreasing the lipidation of VLDL. 9 Importantly, TM6SF2 is also highly expressed in the intestine, which plays an important role in post-prandial lipid absorption by secreting chylomicrons, and lipid absorption was modestly impaired in Tm6sf2-/-mice. 9 Therefore, TM6SF2 variant may also reduce the ability to secrete chylomicrons by enterocytes in humans. In parallel, a retention of chylomicrons occurs in loss-of-function APOB mutations 10 also increasing the risk of to steatosis and progressive liver disease. 
